| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 10/04/2006 | CN1839936A Red sage root extract possessing antithrombotic acitivity and its preparation method |
| 10/04/2006 | CN1839935A Use of red sage root extract in preparing antithrombotic pharmaceutical composition |
| 10/04/2006 | CN1839909A Aizoon stonecrop granule and its preparation process |
| 10/04/2006 | CN1839904A Injection liquid containing glabrous sarcandra herb extract flavone effective part and its uses |
| 10/04/2006 | CN1839903A Pharmaceutical composition containing glabrous sarcandra herb extract and its uses |
| 10/04/2006 | CN1839902A Pharmaceutical composition containing glabrous sarcandra herb extract flavone effective part and its uses |
| 10/04/2006 | CN1839876A Heparin oral nano composition and its preparation method |
| 10/04/2006 | CN1839866A Medicinal composition containing breviscapine |
| 10/04/2006 | CN1839861A Effervesce tablet for dredging thrombosis and its preparation process |
| 10/04/2006 | CN1839859A Ginsenoside F1 medicinal uses |
| 10/04/2006 | CN1839837A Nicorandil freeze-drying powder preparation method |
| 10/04/2006 | CN1839836A Method for preparing nicorandil tablet |
| 10/04/2006 | CN1839824A Emulsion medicine containing n-NBP for injection and its preparation method |
| 10/04/2006 | CN1839823A Compositions useful for the treatment of pathologies responding to the activation of ppar-gamma receptor |
| 10/04/2006 | CN1277828C Piperzine derivative |
| 10/04/2006 | CN1277581C Method for producing antithrombotic medicine by using silk-worm |
| 10/04/2006 | CN1277577C Chinese traditional medicine for treating cerebral thrombosis and application |
| 10/04/2006 | CN1277568C Chinese traditional medicinal composition and its preparation process and usage |
| 10/04/2006 | CN1277550C Wild chrysanthemum oral disintegration tablet and its preparing method |
| 10/04/2006 | CN1277481C Healthy tea |
| 10/03/2006 | US7115769 Catalyzing the alkylation, forming a 2-alkylcysteine derivatives, a chemical intermediates for iron chelating agents |
| 10/03/2006 | US7115741 Anticoagulants and antiagglomerants |
| 10/03/2006 | US7115720 Structurally distinct radionuclide complexes of multinitrogen heterocycles having phosphonic acid groups that target bone, and thus, are useful as imaging and therapeutic agents (e.g., for bone marrow suppression, cancer, bone pain) |
| 10/03/2006 | US7115707 Amino acid sequences capable of facilitating penetration across a biological barrier |
| 10/03/2006 | US7115651 Macrocycles and uses thereof |
| 10/03/2006 | US7115637 Inhibitors of p38 |
| 10/03/2006 | US7115633 Benzosuberonylpiperdine compounds as analgesics |
| 10/03/2006 | US7115627 Trypsin-like serine protease enzyme inhibitors; anticoagulants |
| 10/03/2006 | US7115626 Treatment of cardiovascular and related pathologies |
| 10/03/2006 | US7115625 Administering mixtures of pyridoxal-5'-phosphate, pyridoxal, pyridoxamine, and analogues, angiotensin converting enzyme inhibitors, angiotensin receptor antagonists, vasodilators and diuretics, for prophylaxis of congestive heart failure |
| 10/03/2006 | US7115597 Tyrosine kinase inhibitors |
| 10/03/2006 | US7115588 Applying semi-crystalline acetylglucosamine polysaccharide for treating vasoconstriction, reduction in blood flow |
| 10/03/2006 | US7115585 Compositions for treating epithelial and retinal tissue diseases |
| 10/03/2006 | US7115559 Administering factor XIII to patients afflicted with bleeding due to a coumarin anticoagulant-induced vitamin K deficiency |
| 10/03/2006 | US7115279 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| 10/03/2006 | CA2346438C Utilisation of dialkylfumarates for treating host-versus-graft reactions and auto-immune diseases |
| 10/03/2006 | CA2279535C Dermatan disulfate, an inhibitor of thrombin generation and complement activation |
| 10/03/2006 | CA2277949C Disubstituted bicyclic heterocycles, the preparation and the use thereof as pharmaceutical compositions |
| 09/28/2006 | WO2006100591A1 4-piperazinnylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors |
| 09/28/2006 | WO2006100565A1 Crystalline forms of a known pyrrolidine factor xa inhibitor |
| 09/28/2006 | WO2006046156A3 Anti-diabetic extract isolated from rauvolfia vomitoria and citrus aurantium, and methods of using same |
| 09/28/2006 | US20060217561 Synthesis of substituted thiazoline carboxylic acids |
| 09/28/2006 | US20060217429 Treating stroke or reccurence with an ACE inhibitor selected from quinapril, captropril, lisinopril, perindopril, trandolapril, enalapril, moexipril, fosinopril, ramipril, cilazapril, imidapril, spirapril, temocapril, benazepril, alacepril, ceronapril, delapril, moveltipril and trandolapril |
| 09/28/2006 | US20060217418 Antagonists for melanin concentrating hormone-1 receptors; antidepressants, anxiolytic agents; incontinence, obesity |
| 09/28/2006 | US20060217407 Compositions and Formulations of 9-Nitrocamptothecin Polymorphs and Methods of Use Therefor |
| 09/28/2006 | US20060217364 Beta-lactamyl vasopressin V1a antagonists |
| 09/28/2006 | US20060217296 For treatment and/or prevention of loss of body weight and body fat, cachexia, stimulation of appetite, food intake, stimulation of weight gain, and/or increasing body fat mass |
| 09/28/2006 | US20060216739 Insulin-like growth factor binding protein |
| 09/28/2006 | DE19724791B4 Thrombin hemmende Peptide, deren Verwendung und diese enthaltende pharmazeutische Zusammensetzungen Thrombin-inhibiting peptides, their use and pharmaceutical compositions containing them |
| 09/28/2006 | CA2602550A1 Crystalline forms of a known pyrrolidine factor xa inhibitor |
| 09/28/2006 | CA2602358A1 4-piperazinnylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors |
| 09/27/2006 | EP1705179A1 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 09/27/2006 | EP1705174A1 Selective androgen receptor modulators and methods of use thereof |
| 09/27/2006 | EP1704871A1 Iron supplement and utilization of the same |
| 09/27/2006 | EP1704152A2 Crystalline clopidogrel hydrobromide and processes for preparation thereof |
| 09/27/2006 | EP1703795A2 Beta vulgaris-based products |
| 09/27/2006 | EP1617834B1 Use of a pharmaceutical composition containing lactic acid or lactate and potassium for treating brain edema or brain injury |
| 09/27/2006 | EP1534687B1 2-phenylamino-4-trifluoromethyl-5-(benzyl- or pyridin-4-ylmethyl)carbamoylpyrimidine derivatives as selective cb2 cannabinoid receptor modulators |
| 09/27/2006 | EP1501826B1 Substituted indoles as alpha-1 agonists |
| 09/27/2006 | EP1196433B1 CYCLIC PEPTIDE DERIVATIVES AS INHIBITORS OF INTEGRIN ALPHA v BETA 6 |
| 09/27/2006 | EP1012303B1 Factor x deletion mutants and analogues thereof |
| 09/27/2006 | EP1000079B1 New formulation |
| 09/27/2006 | CN1837207A Pirazino(aza)indole derivatives |
| 09/27/2006 | CN1836699A Multifunctional health liquid |
| 09/27/2006 | CN1836682A Gadol drop pills and preparation method thereof |
| 09/27/2006 | CN1836674A Antler lucid ganoderma and its extract for preparing pharmaceutical and food for treating cancer and immunity effect |
| 09/27/2006 | CN1276764C Use of traditional Chinese composition in preparing medicine for treating iron deficiency anemia |
| 09/26/2006 | US7112666 Von Willebrand Factor (Vwf)-cleaving protease |
| 09/26/2006 | US7112654 Ligand for vascular endothelial growth factor receptor |
| 09/26/2006 | US7112611 Antitumor, anticancer agents; respiratory system disorders; brain disorders |
| 09/26/2006 | US7112603 Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 09/26/2006 | US7112590 Anticoagulant for mammals |
| 09/26/2006 | US7112574 found to be potent adenosine receptor agonists, in particular for the A2A receptor. |
| 09/26/2006 | US7112421 Nucleic acids encoding BAFF receptor, chimeric proteins and methods and compositions related thereto |
| 09/26/2006 | US7112339 Compositions for controlled release of a biologically active agent, and the preparation thereof |
| 09/26/2006 | CA2285383C Glycosaminoglycans having high antithrombotic activity |
| 09/26/2006 | CA2278694C Sulfamide-metalloprotease inhibitors |
| 09/21/2006 | WO2006099154A1 Treating anemia by inhibition of vegf |
| 09/21/2006 | WO2006098353A1 External preparation |
| 09/21/2006 | WO2006097570A1 A combination treatment for enhancing diuresis |
| 09/21/2006 | WO2006059236A3 Method of using cartilage extract for increasing blood parameters |
| 09/21/2006 | WO2006048152A3 Dicarboxamide derivatives and their use as factor xa inhibitors |
| 09/21/2006 | WO2005112897A3 Immediate release pharmaceutical tablets with height greater than width |
| 09/21/2006 | US20060212109 Delivery of therapeutic capable agents |
| 09/21/2006 | US20060211860 Compounds for the treatment of Alzheimer's disease |
| 09/21/2006 | US20060211723 Aporphine and oxoaporphine compounds and pharmaceutical use thereof |
| 09/21/2006 | US20060211719 Heteroaryl aminoguanidine and alkoxyguanidines and their use as protease inhibitors |
| 09/21/2006 | US20060211694 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease |
| 09/21/2006 | US20060211692 reacting cis-hydroxy-D-proline with 4-chlorophenyl iso-cyanate forming intermediate 1(4-chlorophenylcarbamoyl)-4-hydroxypyrrolidine-2-carboxylic acid, reacting intermediate with aminophenylmorpholinone; 1-[(4-chlorophenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide |
| 09/21/2006 | US20060211654 Pharmaceutical Compositions of Cholesteryl Ester Transfer Protein Inhibitor |
| 09/21/2006 | US20060211621 Combined use of factor VII polypeptides and factor IX polypeptides |
| 09/21/2006 | US20060211618 Polynucleotides and polypeptides of the erythropoietin gene |
| 09/21/2006 | US20060211150 Fibronectin and fibrinogen biopolymer markers indicative of insulin resistance |
| 09/21/2006 | US20060211149 Fibronectin and fibrinogen biopolymer markers indicative of insulin resistance |
| 09/21/2006 | US20060211143 Fibronectin and fibrinogen biopolymer markers indicative of insulin resistance |
| 09/21/2006 | US20060211142 Fibronectin and fibrinogen biopolymer markers indicative of insulin resistance |
| 09/21/2006 | US20060210551 Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of a patient subjected to thrombolyses |
| 09/21/2006 | US20060210548 Method for reducing obstructive hydrocephalus |
| 09/21/2006 | CA2601123A1 External preparation |
| 09/21/2006 | CA2599575A1 A combination treatment for enhancing diuresis |